NASDAQ:ASND - Ascendis Pharma A/S Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$68.00 -0.34 (-0.50 %)
(As of 08/14/2018 04:00 PM ET)
Previous Close$68.34
Today's Range$66.25 - $69.05
52-Week Range$26.30 - $76.29
Volume222,200 shs
Average Volume154,171 shs
Market Capitalization$2.81 billion
P/E Ratio-15.72
Dividend YieldN/A
Beta0.67
Ascendis Pharma A/S logoAscendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.

Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ASND
CUSIPN/A
Phone45-7022-2244

Debt

Debt-to-Equity RatioN/A
Current Ratio20.55
Quick Ratio20.55

Price-To-Earnings

Trailing P/E Ratio-15.72
Forward P/E Ratio-15.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.80 million
Price / Sales1,568.53
Cash FlowN/A
Price / CashN/A
Book Value$5.82 per share
Price / Book11.68

Profitability

EPS (Most Recent Fiscal Year)($4.33)
Net Income$-140,040,000.00
Net Margins-12,089.94%
Return on Equity-64.87%
Return on Assets-59.63%

Miscellaneous

Employees137
Outstanding Shares41,520,000
Market Cap$2.81 billion

Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its earnings results on Wednesday, May, 30th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.93) by $0.38. The biotechnology company earned $0.03 million during the quarter, compared to analysts' expectations of $0.30 million. Ascendis Pharma A/S had a negative net margin of 12,089.94% and a negative return on equity of 64.87%. View Ascendis Pharma A/S's Earnings History.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Friday, August, 17th 2018. View Earnings Estimates for Ascendis Pharma A/S.

What price target have analysts set for ASND?

9 equities research analysts have issued 1-year price objectives for Ascendis Pharma A/S's stock. Their predictions range from $51.00 to $85.00. On average, they anticipate Ascendis Pharma A/S's share price to reach $72.00 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price. View Analyst Price Targets for Ascendis Pharma A/S.

What is the consensus analysts' recommendation for Ascendis Pharma A/S?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ascendis Pharma A/S.

Who are some of Ascendis Pharma A/S's key competitors?

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the folowing people:
  • Mr. Michael Wolff Jensen L.L.M., Chairman, Sr. VP, Gen. Counsel and Member of Exec. Board (Age 47)
  • Mr. Jan Møller Mikkelsen, Chief Exec. Officer, Pres, Member of Exec. Board and Exec. Director (Age 58)
  • Mr. Scott T. Smith, Sr. VP & CFO (Age 44)
  • Mrs. Lotte Sønderbjerg, Chief Admin. Officer, Sr. VP and Member of Exec. Board (Age 57)
  • Dr. Grethe Rasmussen Ph.D., Sr. VP of Product Devel. and Member of Exec. Board (Age 56)

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Has Ascendis Pharma A/S been receiving favorable news coverage?

Media headlines about ASND stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ascendis Pharma A/S earned a media and rumor sentiment score of 0.22 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 48.26 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Ascendis Pharma A/S.

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (8.04%), VHCP Management II LLC (1.21%), BlackRock Inc. (1.06%), Artisan Partners Limited Partnership (0.21%), DAFNA Capital Management LLC (0.18%) and TD Asset Management Inc. (0.14%).

Which major investors are selling Ascendis Pharma A/S stock?

ASND stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, VHCP Management II LLC, Alps Advisors Inc., DAFNA Capital Management LLC, Aperio Group LLC, Victory Capital Management Inc. and Vident Investment Advisory LLC.

Which major investors are buying Ascendis Pharma A/S stock?

ASND stock was acquired by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Renaissance Technologies LLC, BlackRock Inc., Bank of America Corp DE, SG Americas Securities LLC, TD Asset Management Inc., Quantitative Systematic Strategies LLC and PNC Financial Services Group Inc..

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $68.00.

How big of a company is Ascendis Pharma A/S?

Ascendis Pharma A/S has a market capitalization of $2.81 billion and generates $1.80 million in revenue each year. The biotechnology company earns $-140,040,000.00 in net income (profit) each year or ($4.33) on an earnings per share basis. Ascendis Pharma A/S employs 137 workers across the globe.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 5, HELLERUP G7, 2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]


MarketBeat Community Rating for Ascendis Pharma A/S (NASDAQ ASND)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  332
MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.